SARS-CoV-2 Spike protein (S1, G75V, T76I, del 247-253, L452Q, F490S, His Tag)

该产品已下架。

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. The SARS-CoV-2 lambda variant was first identified in Peru in August 2020, and has quickly spread to other parts of South America and the United States. WHO classified lambda as a global "variant of interest". This variant carries a number of mutations with suspected implications, such as potential increased transmissibility or possible increased resistance to neutralizing antibodies. However, the full extent of those mutations' impact isn't yet well understood and will need further study. The lambda variant mainly contains L452Q and F400S point mutations in RBD domain, G75V, T76I and deletion mutation of 246-252 are located in S1 domain, which may enhance the infectivity.

产品编号	Z03698
规格	定制报价

联系我们

产品简介

Species

SARS-CoV-2

Protein Construction

Expressed with the mutations of G75V, T76I, del 247-253, L452Q, F490S.

S1 protein (Gln14-Arg685) Accession # P0DTC2	Poly-His
N-term	C-term

Purity

≥ 90% as analyzed by SDS-PAGE

Endotoxin Level

≤ 1 EU/μg of protein by gel clotting method

Biological Activity

This protein is validated to bind with human ACE2 in functional ELISA assay.

Expression System

CHO

Theoretical Molecular Weight

75.7 kDa

Apparent Molecular Weight

~112 kDa, on SDS-PAGE under reducing conditions.

Formulation

Supplied as a solution in PBS, pH 7.4.

Concentration

Please refer to the COA for the specific lot.

Storage & Stability

Upon receiving, this product remains stable for up to 6 months at -20°C or below. Please avoid repeated freeze-thaw cycles.

技术背景

Target Background	SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. The SARS-CoV-2 lambda variant was first identified in Peru in August 2020, and has quickly spread to other parts of South America and the United States. WHO classified lambda as a global "variant of interest". This variant carries a number of mutations with suspected implications, such as potential increased transmissibility or possible increased resistance to neutralizing antibodies. However, the full extent of those mutations' impact isn't yet well understood and will need further study. The lambda variant mainly contains L452Q and F400S point mutations in RBD domain, G75V, T76I and deletion mutation of 246-252 are located in S1 domain, which may enhance the infectivity.
Synonyms	C.37; Lambda variant
References	1. Tracking SARS-CoV-2 variants. 2. SARS-CoV-2 lambda variant escapes immune response via spike mutations. 3. It Is Time To Pay Close Attention To The Lambda Variant Now Devastating South America.